nach oben

Erschienen in:

24.03.2020 | Original Research

Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination

verfasst von: Shereen El Shorbagy, Fouad abuTaleb, Hany A. Labib, Huda Ebian, Ola A. Harb, Mona Saeed Mohammed, Hanaa A. Rashied, Khaled A. Elbana, Rasha Haggag

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Hepatocellular carcinoma (HCC) is a major health problem. HCC burden has been increasing in Egypt in the past 10 years. Most HCC cases are diagnosed at an advanced stage with limited treatment options. Sorafenib is the standard therapy for advanced HCC, but the effectiveness is not satisfied. Metformin may decrease the risk of HCC development in diabetic patients, reduces tumor invasion, and augments sensitivity to sorafenib; however, safety and efficacy of combined treatment are still unclear. As HCC is characterized by high vascularity, and vascular endothelial growth factor (VEGF) plays an important role in vascularization, many studies questioned if VEGF and HIF-1 α could offer information about HCC response to sorafenib. We conducted this study to assess the benefits from adding metformin to HCC treatment, and appraise the role of VEGF and HIF-1 α in HCC prognosis.

Method

This was a prospective, randomized study in which 80 advanced measurable patients consecutively treated with sorafenib plus metformin (arm A) or sorafenib alone (arm B), prognostic value of plasma, and tissue levels of VEGF and HIF-1 α were evaluated.

Results

We enrolled 61 men and 19 women with a median age of 60 years (range 49–68 years). Fifty-seven patients had Child–Pugh A while 23 had early B, the most common etiology of liver disease was hepatitis C (86%). Sixty percent of patients were diabetic. No significant difference was detected between arm A and arm B regarding response to treatment (p = 0.5), time to disease progression (p = 0.3), or overall survival (p = 0.6). Low VEGF and HIF-1 α plasma levels were significantly associated with better treatment response (p < 0.001 for both), and higher OS (p < 0.001). Patients with high expressions of VEGF and HIF in HCC tissue had significantly poor treatment outcome (p < 0.001, p = 0.03, respectively), and poor OS (p < 0.001, p < 0.001, respectively).

Conclusions

No superior efficacy of adding metformin to sorafenib in HCC treatment. VEGF and HIF-1 α had promising prognostic value in HCC.

Hollebecque A, Malka D, Ferte C, et al. Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons. Eur J Cancer. 2015;51:327–39.PubMed

Balogh J, Victor D, Asham EH, Gordon S, Boktour M. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;2016(3):41–53.

Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel HA. Cancer incidence in Egypt: results of the National Population-Based Cancer Registry Program. J Cancer Epidemiol. 2014;2014:437971.PubMedPubMedCentral

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMed

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.PubMed

Crissien AM, Frenette C. Current management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 2014;10(3):153–61.

Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut. 2013;62:606–15.PubMed

Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574–9.PubMed

Ben Sahra I, Regazzetti C, Robert G, et al. Metformin, independent of AMPK, induces mTOR inhibition and cell - cycle arrest through REDD1. Cancer Res. 2011;71:4366e72.

10.

Singh S, Singh PP, Singh AG, et al. Antidiabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am J Gastroenterol. 2013;108:881–91 quiz 892.PubMed

11.

Zhan P, Qian Q, Yu L-K. Serum VEGF level is associated with the outcome of patients with hepatocellular carcinoma: a meta-analysis. Hepatobiliary Surg Nutr. 2013;2(4):209–15.PubMedPubMedCentral

12.

Zhao J, Hu J, Cai J, Yang X, Yang Z. Vascular endothelial growth factor expression in serum of patients with hepato-cellular carcinoma. Chin Med J. 2003;116:772–6.PubMed

13.

Liu Y, Poon RT, Li Q, Kok TW, Lau C, Fan ST. Both anti-angiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2005;65:3691–9.PubMed

14.

Schoenleber SJ, Kurtz DM, Talwalkar JA, et al. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. Br J Cancer. 2009;100:1385–92.PubMedPubMedCentral

15.

Myung SJ, Yoon J. Hypoxia in hepatocellular carcinoma. Korean J Hepatol. 2007;13(1):9–19.PubMed

16.

Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12(12):5447–54.PubMedPubMedCentral

17.

Hong SS, Lee H, Kim KW. HIF-1alpha: a valid therapeutic target for tumor therapy. Cancer Res Treat. 2004;36(6):343–53.PubMedPubMedCentral

18.

Burroughs SK, Kaluz S, Wang D, Wang K, Van Meir EG, Wang B. Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Med Chem. 2013;5(5):553–72.PubMed

19.

Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–27.PubMed

20.

Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res. 2013;5:337–47.PubMedPubMedCentral

21.

Liu L, Ho RLK, Chen GG, Lai PBS. Sorafenib inhibits hypoxia-inducible factor-1alpha synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin Cancer Res. 2012;18(20):5662–71.PubMed

22.

Wang W, Xu G, Jia WD, et al. Expression and correlation of hypoxia-inducible factor-1α, vascular endothelial growth factor and microvessel density in experimental rat hepatocarcinogenesis. J Int Med Res. 2009;37(2):417–25.PubMed

23.

Li S, Yao D, Wang L, et al. Expression characteristics of hypoxia-inducible factor-1α and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Hepat Mon. 2011;11(10):821–8.PubMedPubMedCentral

24.

Zheng S, Chen X, Yin X, Zhang B. Prognostic significance of HIF-1a expression in hepatocellular carcinoma: a meta-analysis. PLoS One. 2013;8(6):e65753.PubMedPubMedCentral

25.

Cao S, Yang S, Wu C, et al. Protein expression of hypoxia-inducible factor-1 alpha and hepatocellular carcinoma: a systematic review with meta-analysis. Clin Res Hepatol Gastroenterol. 2014;S2210-7401(14):2014.

26.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16.PubMed

27.

Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem. 1981;29:577.PubMed

28.

Xiang ZL, Zeng ZC, Fan J, Tang ZY, He J, Zeng HY, et al. The expression of HIF-1alpha in primary hepatocellular carcinoma and its correlation with radiotherapy response and clinical outcome. Mol Biol Rep. 2012;39:2021–9.PubMed

29.

Dai CX, Gao Q, Qiu SJ, et al. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer. 2009;9:418.PubMedPubMedCentral

30.

Xiang ZL, Zeng ZC, Fan J, Tang ZY, Zeng HY, Gao DM. Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1alpha, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res. 2011;17:5463–72.PubMed

31.

Xie H, Song J, Liu K, Ji H, Shen H, Hu S, et al. The expression of hypoxia-inducible factor-1alpha in hepatitis B virus-related hepatocellular carcinoma: correlation with patients’ prognosis and hepatitis B virus X protein. Dig Dis Sci. 2008;53:3225–33.PubMed

32.

Staibano S, Mascolo M, Di Benedetto M, et al. BAG3 protein delocalisation in prostate carcinoma. Tumor Biol. 2010;31(5):461–9.

33.

Basa N, Cornianu M, Lazar E, Dema A, Taban S, Lazar D, et al. Immunohistochemical expression of VEGF in hepatocellular carcinoma and surrounding liver tissue. Seria Ştiinţele Vieţii. 2011;21:479–86.

34.

Guan Q, Junpeng G, Zhang H, Ren W. Correlation between vascular endothelial growth factor levels and prognosis of hepatocellular carcinoma patients receiving radiofrequency ablation. Biotechnol Biotechnol Equip. 2015;29(1):119–23.PubMed

35.

Dabrowski M. Glycated hemoglobin, diabetes treatment and cancer risk in type 2 diabetes. A case-control study. Ann Agric Environ Med. 2013;20:116–21.PubMed

36.

Li CI, Chen HJ, Lai HC, Liu CS, Lin WY, Li TC, et al. Hyperglycemia and chronic liver diseases on risk of hepatocellular carcinoma in Chinese patients with type 2 diabetes–National cohort of Taiwan Diabetes Study. Int J Cancer. 2015;136:2668–79.PubMed

37.

Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010;30:750–8.PubMed

38.

Sluik D, Boeing H, Montonen J, et al. HbA1c measured in stored erythrocytes is positively linearly associated with mortality in individuals with diabetes mellitus. PLoS One. 2012;7:e38877.PubMedPubMedCentral

39.

de Beer JC, Liebenberg L. Does cancer risk increase with HbA1c, independent of diabetes? BJC. 2014;110:2361–8.PubMed

40.

Yang X, Ko GT, So WY, et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes. 2010;59:1254–60.PubMedPubMedCentral

41.

Bhat M, Chaiteerakij R, Harmsen WS, Schleck CD, Yang JD, et al. Metformin does not improve survival in patients with hepatocellular carcinoma. World J Gastroenterol. 2014;20(42):15750–5 ISSN 1007–9327 (print) ISSN 2219–2840 (online).PubMedPubMedCentral

42.

Gardini C, Marisi G, Scarpi E, Scartozzi M. Metformin effects on clinical outcome in advanced HCC patients receiving sorafenib: validation study. Eur J Cancer. 2017; http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.e15684.

43.

Ma SJ, Zheng YX, Zhou PC, Xiao YN, Tan HZ. Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis. Oncotarget. 2016;7(40):66202–11. https://doi.org/10.18632/oncotarget.11033.CrossRefPubMedPubMedCentral

44.

Liu L, Zhu XD, Wang WQ, Shen Y, Qin Y, Ren ZG, et al. Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin Cancer Res. 2010;16:2740–50.PubMed

45.

Huang GW, Yang LY, Lu WQ. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival. World J Gastroenterol. 2005;11:1705–8.PubMedPubMedCentral

46.

Xia L, Mo P, Huang W, Zhang L, Wang Y, et al. The TNF-alpha/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis. Carcinogenesis. 2012;33:2250–9.PubMed

47.

Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int. 2006;26:414–23.PubMed

Titel: Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination
verfasst von: Shereen El Shorbagy
Fouad abuTaleb
Hany A. Labib
Huda Ebian
Ola A. Harb
Mona Saeed Mohammed
Hanaa A. Rashied
Khaled A. Elbana
Rasha Haggag
Publikationsdatum: 24.03.2020
Verlag: Springer US
Erschienen in: Journal of Gastrointestinal Cancer / Ausgabe 1/2021
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-020-00389-w

Springer Medizin

Prognostic Significance of VEGF and HIF-1 α in Hepatocellular Carcinoma Patients Receiving Sorafenib Versus Metformin Sorafenib Combination